(Q38062020)

28 August 2017

1 reference

title

Treatment options for advanced pancreatic cancer: a review (English)

1 reference

28 August 2017

1 reference

Rahma Warsame

1

1 reference

PubMed ID

23176620

28 August 2017

Axel Grothey

series ordinal

2

1 reference

28 August 2017

1 October 2012

1 reference

Expert Review of Anticancer Therapy

28 August 2017

1 reference

28 August 2017

12

1 reference

28 August 2017

10

1 reference

28 August 2017

1327-1336

1 reference

28 August 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/ 5-fluorouracil every 2 weeks in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer--a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Regulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by an insulin-like growth factor-I receptor autocrine loop in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Overcoming drug resistance in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

RETRACTED: 3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A paracrine requirement for hedgehog signalling in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Hedgehog signaling and therapeutics in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.12.115

21 January 2018

Identifiers

DOI

10.1586/ERA.12.115

1 reference

28 August 2017

1 reference

PubMed ID

23176620